This underscores the critical role of PD-L1 expression level detection, which may serve as a strategy to enhance the cost-effectiveness of CAD-CHM in treating HER2-negative advanced G/GEJ adenocarcinoma. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.